Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant fulvestrant 500 mg vs 250 mg in postmenopausal women with ER-positive breast cancer
2004-003617-16Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fulvestrant in estrogen receptor-positive breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoints: Change in Ki67 proliferation index at 4 weeks and Tumor marker changes at 4 and 16 weeks. Started Nov 2004; status: completed.
02
Drugs
fulvestrant
03
Conditions
estrogen receptor-positive breast cancer
Beyond the preview
Go deeper on 2004-003617-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003617-16.